{"id":"W4286298696","doi":"10.1200/jco.2022.40.16_suppl.4560","title":"Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Avelumab; Medicine; Internal medicine; Metastatic Urothelial Carcinoma; Discontinuation; Maintenance therapy; Randomization; Gemcitabine; Oncology; Bladder cancer; Surgery; Gastroenterology; Chemotherapy; Urology; Nivolumab; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001914261,0.0004712033,0.000951677,0.0002834212,0.0002742404,0.0007190569,0.0005031346,0.0006776135,0.001591478],"category_scores_gemma":[0.001584785,0.0002983786,0.002348157,0.0003986132,0.0004997673,0.0006442349,0.000656507,0.001386169,0.0002498054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007455429,"about_ca_system_score_gemma":0.0006643935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005324977,"about_ca_topic_score_gemma":0.001271019,"domain_scores_codex":[0.9993468,0.0002851813,0.00004742658,0.000126432,0.00006961782,0.0001246],"domain_scores_gemma":[0.9982955,0.0004206332,0.0005236268,0.0001626062,0.0000641494,0.0005334805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6889038,0.01026527,0.2411762,0.0008112722,0.005907199,0.000404499,0.000293398,0.002424546,0.00905666,0.0002193356,0.002251983,0.03828586],"study_design_scores_gemma":[0.09571372,0.2828856,0.6044943,0.0001895914,0.00554135,0.0008583798,0.0003131472,0.00339815,0.002926582,0.0005514146,0.003035328,0.00009255276],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978198,0.001051551,0.00009622824,0.00005377738,0.00001297033,0.00009146008,0.0005584017,0.000006582338,0.0003092267],"genre_scores_gemma":[0.9973961,0.0003202939,0.0001627779,0.0001386062,0.00004127065,0.0001777393,0.001455796,0.000003679423,0.0003038446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001914261,"threshold_uncertainty_score":0.01012373,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1344244734599757,"score_gpt":0.4257519701847146,"score_spread":0.2913274967247389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}